Rhumbline Advisers Has $6.32 Million Position in Omnicell, Inc. (NASDAQ:OMCL)

Rhumbline Advisers decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 141,870 shares of the company’s stock after selling 588 shares during the period. Rhumbline Advisers’ holdings in Omnicell were worth $6,316,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Creative Planning lifted its holdings in Omnicell by 23.1% during the 3rd quarter. Creative Planning now owns 11,667 shares of the company’s stock valued at $509,000 after purchasing an additional 2,188 shares during the last quarter. Roubaix Capital LLC acquired a new stake in shares of Omnicell during the third quarter worth approximately $1,851,000. 1620 Investment Advisors Inc. lifted its holdings in Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Omnicell in the 3rd quarter valued at $2,723,000. Finally, QRG Capital Management Inc. bought a new stake in shares of Omnicell during the third quarter worth $231,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Price Performance

OMCL stock opened at $39.73 on Thursday. The company’s 50-day moving average price is $42.65 and its two-hundred day moving average price is $43.85. The firm has a market cap of $1.84 billion, a P/E ratio of 147.15, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on OMCL. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. lifted their price objective on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Wells Fargo & Company cut their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Craig Hallum upped their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Insider Buying and Selling

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.64% of the stock is owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.